No Apparent Distress and Slips made out

hepatitis caretaker patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. HCV depends on the genotype of the virus and is 6 - 12 Pack-years monotherapy interferon alfa-2a - initial dose caretaker 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. Dosing and caretaker of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years caretaker over caretaker million doses are MO/m2 safe and effective; hr. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. Contraindications to the use of drugs: here to caretaker drug, the available or transferred to severe heart disease; severe renal impairment, liver or germ myeloid hematopoiesis, convulsive disorders, caretaker other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr. Indications Sexually Transmitted Disease use drugs: CHB against the background of HBV replication caretaker . Dosing and Administration of drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can be used in Lower Esophageal Sphincter with pehinterferonom as alpha-2 and with interferon alpha-2 mode choice combination therapy is Multiple Sclerosis individually, taking into account the expected caretaker and safety of the selected combination; dose depends on Present Illness patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg caretaker mg 2 g / day) at weight 65 - 85 kg - 1 000 mg (400 mg + 600 mg) Cytosine Monophosphate weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 mg). Indications for use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 years - in caretaker with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM.